Clinical Trial Update: CAR T Cells for Refractory B Cell Malignancy [Phase 1, Phase 2]

View source ↗

Summary

This entry reports an ongoing Phase 1/Phase 2 trial of CAR T cell therapy for refractory B-cell malignancies, including B-cell leukemia and B-cell lymphoma, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma

Snippet

Sponsor: Hebei Senlang Biotechnology Inc., Ltd. | Conditions: B-Cell Leukemia, B-Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN